0
0.5
1
1.5
2+
Death/hospitalization
61%
Improvement
Relative Risk
Hospitalization
61%
Casirivimab/i.. Wei et al. EARLY TREATMENT
Is early treatment with casirivimab/imdevimab beneficial for COVID-19?
Retrospective 19,564 patients in the USA (December 2020 - June 2021)
Lower death/hosp. (p<0.0001) and hospitalization (p<0.0001)
c19early.org
Wei et al., medRxiv, February 2022
Favors casirivimab/im..
Favors control